Oncology Drugs

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

With major grants from top foundations, Lario Therapeutics expands its precision neuroscience platform, offering new hope for complex neurological disorders.

Flatiron Health launches a first-of-its-kind AI platform, merging data from 400,000 patients to revolutionize prostate cancer research and treatment.

A novel drug candidate targeting treatment-resistant kidney disease has begun its long journey through clinical trials, signaling a major strategic push.

New Directions Mental Health adds cutting-edge Spravato and TMS therapies, expanding access for Pennsylvanians with treatment-resistant depression.

With a $50.1M financing led by top investors, Coherus solidifies its strategic pivot from biosimilars to a pure-play oncology powerhouse.

Cindy Eckert's TIME100 nod follows a major FDA win for her libido drug, Addyi, but spotlights a decade-long battle over efficacy, safety, and equality.

A major patent deal shields Esperion's flagship drugs from generics, securing future revenue but delaying cheaper options for millions of patients.

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

Bausch Health heads to a key finance conference to address investor concerns over its massive debt, upcoming patent cliffs, and future strategic direction.

A landmark trial shows Retevmo significantly cuts cancer recurrence in early-stage patients, pushing for a new standard of care and early genetic testing.

A landmark trial for Roche’s Gazyva shows unprecedented success in treating primary membranous nephropathy, offering hope of preventing kidney failure.

Nicox's novel glaucoma drug NCX 470 receives positive FDA feedback, keeping its 2026 U.S. market submission on track to challenge a $7B industry.

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

With a new chair from Genmab and a board of industry titans, BioNJ is poised to bolster New Jersey's status as a global biotech powerhouse.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

With promising new data for its cancer and obesity pipeline, Corbus Pharmaceuticals prepares for a crucial investor presentation at the Oppenheimer conference.

A new drug, JIN-A02, shows early promise in overcoming resistance to common lung cancer therapies, even shrinking hard-to-treat brain metastases.